DDR Corp. (NYSE:DDR) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it 2.95% to close at $14.32 with the total traded volume of 21.83 Million shares. DDR Corp. (DDR) reported that David Lukes has been named President and CEO to replace Tom August. The company also reported the appointment of Michael Makinen as Executive Vice President and Chief Operating Officer and Matthew Ostrower as Executive Vice President, Chief Financial Officer, and Treasurer.
David Lukes served as CEO of Equity One from June 2014 to March 2017. Prior to joining Equity One, he served as President and CEO of Sears Holdings Corporation affiliate Seritage Realty Trust. Lukes also previously served as President and CEO of Olshan Properties as well as Chief Operating Officer of Kimco Realty Corporation.
Mike Makinen served as Executive Vice President and Chief Operating Officer of Equity One from July 2014 to March 2017. Prior to joining Equity One, Makinen served as Chief Operating Officer of Olshan Properties. Matthew Ostrower served as Executive Vice President, Chief Financial Officer and Treasurer of Equity One from March 2015 to March 2017. Prior to joining Equity One, Ostrower held several roles at Morgan Stanley, including Associate Director of European Research and head of U.S. REIT Equity Research. The firm has institutional ownership of 90.10%, while insider ownership included 11.80%. Its price to sales ratio ended at 5.26. DDR attains analyst recommendation of 3.00 with week’s performance of -2.32%.
Amgen Inc. (NASDAQ:AMGN) [Trend Analysis] moved up reacts as active mover, shares an advance 1.20% to traded at $180.20 and the percentage gap between open changing to regular change was 0.22%. Amgen (AMGN) reported that its positive results from a planned overall survival (OS) interim analysis of the Phase 3 head-to-head ENDEAVOR trial. The study met the key secondary endpoint of OS, demonstrating that patients with relapsed or refractory multiple myeloma treated with KYPROLIS (carfilzomib) and dexamethasone (Kd) lived 7.6 months longer than those treated with Velcade (bortezomib) and dexamethasone (Vd) (median OS 47.6 months for Kd versus 40.0 for Vd, HR=0.79; 95 percent CI: 0.65 – 0.96; p=0.01). The OS benefit was consistent regardless of prior Velcade therapy (HR 0.75 for no prior Velcade; HR 0.84 for prior Velcade). These data will be presented during the late-breaking abstract session at the 16th International Myeloma Workshop (IMW) in New Delhi.
The firm’s current ratio calculated as 4.10 for the most recent quarter. The firm past twelve months price to sales ratio was 5.75 and price to cash ratio remained 3.47. As far as the returns are concern, the return on equity was recorded as 25.90% and return on investment was 13.00% while its return on asset stayed at 10.10%. The firm has total debt to equity ratio measured as 1.16.